An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D, Teoh G, Lau LC, Lim A, Lim TH, Yap KC, Premalatha P, Lao ZT, Wee N, Choo C, Wee HC, Su S, Lee YS, Lee LH, Hwang W, Goh YT.
Tan D, et al. Among authors: lim th, lim a.
Am J Hematol. 2010 Oct;85(10):752-6. doi: 10.1002/ajh.21812.
Am J Hematol. 2010.
PMID: 20721886
Free article.